Cargando…

Growth Arrest-Specific 6 in Chromophobe Renal Cell Carcinoma

BACKGROUND: Overexpression of tumor-associated growth arrest-specific protein 6 (Gas6) is found in many tumor entities. The prognostic value of Gas6 in renal cell carcinoma (RCC), especially in non-clear cell RCC, is still unclear. AIM: The aim of the study was to evaluate the prognostic impact of G...

Descripción completa

Detalles Bibliográficos
Autores principales: Mikuteit, Marie, Zschäbitz, Stefanie, Erlmeier, Maximilian, Autenrieth, Michael, Weichert, Wilko, Hartmann, Arndt, Steffens, Sandra, Erlmeier, Franziska
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9677856/
https://www.ncbi.nlm.nih.gov/pubmed/35760058
http://dx.doi.org/10.1159/000525601
_version_ 1784833881206161408
author Mikuteit, Marie
Zschäbitz, Stefanie
Erlmeier, Maximilian
Autenrieth, Michael
Weichert, Wilko
Hartmann, Arndt
Steffens, Sandra
Erlmeier, Franziska
author_facet Mikuteit, Marie
Zschäbitz, Stefanie
Erlmeier, Maximilian
Autenrieth, Michael
Weichert, Wilko
Hartmann, Arndt
Steffens, Sandra
Erlmeier, Franziska
author_sort Mikuteit, Marie
collection PubMed
description BACKGROUND: Overexpression of tumor-associated growth arrest-specific protein 6 (Gas6) is found in many tumor entities. The prognostic value of Gas6 in renal cell carcinoma (RCC), especially in non-clear cell RCC, is still unclear. AIM: The aim of the study was to evaluate the prognostic impact of Gas6 expression in a large cohort of patients with chromophobe RCC (chRCC). MATERIAL AND METHODS: Patients who underwent renal surgery due to chRCC were retrospectively evaluated. Tumor specimens were analyzed for Gas6 expression by immunohistochemistry. RESULTS: Eighty-one chRCC patients were eligible for analysis; of these, 24 (29.6%) patients were positive for Gas6. No significant associations were found for Gas6 expression and clinical attributes in patients with chRCC. The Kaplan-Meier analysis revealed no differences in 5-year overall survival for Gas6− compared to Gas6+ (89.6% vs. 100.0%; p = 0.288) tumors. CONCLUSION: In chRCC, Gas6 expression is not associated with survival and other parameters of aggressiveness. Due to the rare incidence of chRCC, further studies with larger cohorts are warranted.
format Online
Article
Text
id pubmed-9677856
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher S. Karger AG
record_format MEDLINE/PubMed
spelling pubmed-96778562022-11-22 Growth Arrest-Specific 6 in Chromophobe Renal Cell Carcinoma Mikuteit, Marie Zschäbitz, Stefanie Erlmeier, Maximilian Autenrieth, Michael Weichert, Wilko Hartmann, Arndt Steffens, Sandra Erlmeier, Franziska Oncology Clinical Study BACKGROUND: Overexpression of tumor-associated growth arrest-specific protein 6 (Gas6) is found in many tumor entities. The prognostic value of Gas6 in renal cell carcinoma (RCC), especially in non-clear cell RCC, is still unclear. AIM: The aim of the study was to evaluate the prognostic impact of Gas6 expression in a large cohort of patients with chromophobe RCC (chRCC). MATERIAL AND METHODS: Patients who underwent renal surgery due to chRCC were retrospectively evaluated. Tumor specimens were analyzed for Gas6 expression by immunohistochemistry. RESULTS: Eighty-one chRCC patients were eligible for analysis; of these, 24 (29.6%) patients were positive for Gas6. No significant associations were found for Gas6 expression and clinical attributes in patients with chRCC. The Kaplan-Meier analysis revealed no differences in 5-year overall survival for Gas6− compared to Gas6+ (89.6% vs. 100.0%; p = 0.288) tumors. CONCLUSION: In chRCC, Gas6 expression is not associated with survival and other parameters of aggressiveness. Due to the rare incidence of chRCC, further studies with larger cohorts are warranted. S. Karger AG 2022-10 2022-06-27 /pmc/articles/PMC9677856/ /pubmed/35760058 http://dx.doi.org/10.1159/000525601 Text en Copyright © 2022 by The Author(s). Published by S. Karger AG, Basel https://creativecommons.org/licenses/by/4.0/This article is licensed under the Creative Commons Attribution 4.0 International License (CC BY). Usage, derivative works and distribution are permitted provided that proper credit is given to the author and the original publisher.
spellingShingle Clinical Study
Mikuteit, Marie
Zschäbitz, Stefanie
Erlmeier, Maximilian
Autenrieth, Michael
Weichert, Wilko
Hartmann, Arndt
Steffens, Sandra
Erlmeier, Franziska
Growth Arrest-Specific 6 in Chromophobe Renal Cell Carcinoma
title Growth Arrest-Specific 6 in Chromophobe Renal Cell Carcinoma
title_full Growth Arrest-Specific 6 in Chromophobe Renal Cell Carcinoma
title_fullStr Growth Arrest-Specific 6 in Chromophobe Renal Cell Carcinoma
title_full_unstemmed Growth Arrest-Specific 6 in Chromophobe Renal Cell Carcinoma
title_short Growth Arrest-Specific 6 in Chromophobe Renal Cell Carcinoma
title_sort growth arrest-specific 6 in chromophobe renal cell carcinoma
topic Clinical Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9677856/
https://www.ncbi.nlm.nih.gov/pubmed/35760058
http://dx.doi.org/10.1159/000525601
work_keys_str_mv AT mikuteitmarie growtharrestspecific6inchromophoberenalcellcarcinoma
AT zschabitzstefanie growtharrestspecific6inchromophoberenalcellcarcinoma
AT erlmeiermaximilian growtharrestspecific6inchromophoberenalcellcarcinoma
AT autenriethmichael growtharrestspecific6inchromophoberenalcellcarcinoma
AT weichertwilko growtharrestspecific6inchromophoberenalcellcarcinoma
AT hartmannarndt growtharrestspecific6inchromophoberenalcellcarcinoma
AT steffenssandra growtharrestspecific6inchromophoberenalcellcarcinoma
AT erlmeierfranziska growtharrestspecific6inchromophoberenalcellcarcinoma